Hantz Financial Services Inc. lifted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 10.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 298,842 shares of the company’s stock after buying an additional 29,192 shares during the quarter. Hantz Financial Services Inc.’s holdings in Takeda Pharmaceutical were worth $5,436,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of TAK. Provenance Wealth Advisors LLC purchased a new stake in Takeda Pharmaceutical in the 3rd quarter worth $27,000. Nisa Investment Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 28.8% in the third quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company’s stock valued at $42,000 after acquiring an additional 515 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in shares of Takeda Pharmaceutical in the third quarter valued at about $59,000. Pinnacle Wealth Planning Services Inc. lifted its position in shares of Takeda Pharmaceutical by 9.9% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 7,881 shares of the company’s stock valued at $143,000 after acquiring an additional 711 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the second quarter worth about $163,000. Institutional investors own 9.17% of the company’s stock.
Insider Buying and Selling at Takeda Pharmaceutical
In other news, insider Andrew Plump sold 116,191 shares of Takeda Pharmaceutical stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total value of $2,148,371.59. Following the sale, the insider directly owned 145,465 shares of the company’s stock, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lauren Duprey sold 34,535 shares of Takeda Pharmaceutical stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the sale, the insider directly owned 191,522 shares in the company, valued at $3,550,817.88. This trade represents a 15.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 225,994 shares of company stock valued at $4,314,393 in the last 90 days. Insiders own 0.04% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on TAK shares. Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, November 3rd. Zacks Research raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen cut Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Buy”.
Read Our Latest Report on Takeda Pharmaceutical
Takeda Pharmaceutical Stock Performance
Shares of NYSE TAK opened at $21.59 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15. The company has a market cap of $69.17 billion, a P/E ratio of 12.07 and a beta of -0.02. The firm’s fifty day moving average is $19.47 and its two-hundred day moving average is $17.81. Takeda Pharmaceutical Co. has a 52-week low of $13.91 and a 52-week high of $21.86.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
Featured Stories
- Five stocks we like better than Takeda Pharmaceutical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
